JP7731288B2 - アルファ－１－アンチトリプシン欠乏症のための組成物及び方法 - Google Patents

アルファ－１－アンチトリプシン欠乏症のための組成物及び方法

Info

Publication number
JP7731288B2
JP7731288B2 JP2021548539A JP2021548539A JP7731288B2 JP 7731288 B2 JP7731288 B2 JP 7731288B2 JP 2021548539 A JP2021548539 A JP 2021548539A JP 2021548539 A JP2021548539 A JP 2021548539A JP 7731288 B2 JP7731288 B2 JP 7731288B2
Authority
JP
Japan
Prior art keywords
alpha
seq
antitrypsin
residues
serum albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548539A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020092448A5 (https=
JP2022509517A (ja
JP2022509517A5 (https=
Inventor
アーロン サト，
マーク デソウザ，
Original Assignee
スピン セラピューティクス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スピン セラピューティクス， エルエルシー filed Critical スピン セラピューティクス， エルエルシー
Publication of JP2022509517A publication Critical patent/JP2022509517A/ja
Publication of JPWO2020092448A5 publication Critical patent/JPWO2020092448A5/ja
Publication of JP2022509517A5 publication Critical patent/JP2022509517A5/ja
Priority to JP2024103143A priority Critical patent/JP2024123234A/ja
Application granted granted Critical
Publication of JP7731288B2 publication Critical patent/JP7731288B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021548539A 2018-10-29 2019-10-29 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法 Active JP7731288B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103143A JP2024123234A (ja) 2018-10-29 2024-06-26 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752182P 2018-10-29 2018-10-29
US62/752,182 2018-10-29
PCT/US2019/058673 WO2020092448A1 (en) 2018-10-29 2019-10-29 Compositions and methods for alpha-1-antitrypsin disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103143A Division JP2024123234A (ja) 2018-10-29 2024-06-26 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022509517A JP2022509517A (ja) 2022-01-20
JPWO2020092448A5 JPWO2020092448A5 (https=) 2022-11-08
JP2022509517A5 JP2022509517A5 (https=) 2022-11-08
JP7731288B2 true JP7731288B2 (ja) 2025-08-29

Family

ID=68771752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548539A Active JP7731288B2 (ja) 2018-10-29 2019-10-29 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
JP2024103143A Pending JP2024123234A (ja) 2018-10-29 2024-06-26 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103143A Pending JP2024123234A (ja) 2018-10-29 2024-06-26 アルファ－１－アンチトリプシン欠乏症のための組成物及び方法

Country Status (9)

Country Link
US (2) US12497441B2 (https=)
EP (1) EP3873926A1 (https=)
JP (2) JP7731288B2 (https=)
KR (1) KR20210111245A (https=)
CN (1) CN113286816B (https=)
AU (1) AU2019369403B2 (https=)
BR (1) BR112021008200A2 (https=)
CA (1) CA3117961A1 (https=)
WO (1) WO2020092448A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3914261A4 (en) 2019-01-22 2023-06-28 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
KR20210129646A (ko) 2019-01-22 2021-10-28 코로 바이오, 인크. Rna-편집 올리고뉴클레오타이드 및 그의 용도
TW202043469A (zh) 2019-01-22 2020-12-01 美商科羅生物公司 Ｒｎａ編輯之寡核苷酸及其用途
AU2021279027A1 (en) * 2020-05-28 2022-12-08 Korro Bio, Inc. Methods and compositions for the ADAR-mediated editing of SERPINA1
EP4240323A1 (en) * 2020-11-06 2023-09-13 AATEC Medical GmbH A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
IL303712A (en) * 2020-12-18 2023-08-01 Cullinan Amber Corp Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereofלטו
CN117942275A (zh) * 2022-10-31 2024-04-30 康码（上海）生物科技有限公司 一种基于病毒阻断剂的洗手液及其应用
EP4705336A1 (en) * 2023-05-05 2026-03-11 Paul Thomas King Novel therapeutic polypeptide
EP4730999A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat transplants
EP4480493A1 (en) 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523900A (ja) 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
CA2386180C (en) 1999-10-13 2010-03-09 Immunex Corporation Vectors and methods for recombinant protein expression
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003244515A1 (en) 2002-02-07 2003-09-02 Novozymes Delta Limited Albumin-fused anti-angiogenesis peptides
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US20070269442A1 (en) 2006-05-19 2007-11-22 Robert J. Webber Chimeric monoclonal antibody recognizing iNOS
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
US20100048680A1 (en) 2007-01-11 2010-02-25 University Of Florida Research Foundation Inc. Alpha-1-Antitrypsin Variants and Uses Thereof
KR100992526B1 (ko) 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US8341615B2 (en) 2008-07-11 2012-12-25 International Business Machines Corporation Single instruction multiple data (SIMD) code generation for parallel loops using versioning and scheduling
WO2010123290A2 (ko) 2009-04-22 2010-10-28 (주)알테오젠 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
GB201322091D0 (en) * 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
SG11201703390SA (en) 2014-10-27 2017-05-30 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof
WO2018183705A1 (en) 2017-03-29 2018-10-04 Cornell University Oxidation-resistant aat gene therapy
CN110092828B (zh) 2018-01-31 2021-08-24 北京大学 重组突变体α1-抗胰蛋白酶及其制备和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523900A (ja) 2011-06-28 2014-09-18 インヒブルクス リミティド ライアビリティ カンパニー セルピン融合ポリペプチド及びその使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Protein Science，2007年，Vol.16，p.1842-1850
The Journal of Biological Chemistry，1999年，Vol.274, No.14，p.9548-9555
The Journal of Biological Chemistry，2000年，Vol.275, No.35，p.27258-27265
The Journal of Biological Chemistry，2003年，Vol.278, No.35，p.33060-33066

Also Published As

Publication number Publication date
BR112021008200A2 (pt) 2021-12-14
CA3117961A1 (en) 2020-05-07
CN113286816A (zh) 2021-08-20
AU2019369403A1 (en) 2021-05-20
WO2020092448A1 (en) 2020-05-07
JP2022509517A (ja) 2022-01-20
KR20210111245A (ko) 2021-09-10
US20210388059A1 (en) 2021-12-16
US12497441B2 (en) 2025-12-16
US20260092099A1 (en) 2026-04-02
JP2024123234A (ja) 2024-09-10
CN113286816B (zh) 2025-04-04
EP3873926A1 (en) 2021-09-08
AU2019369403B2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7731288B2 (ja) アルファ－１－アンチトリプシン欠乏症のための組成物及び方法
KR102507853B1 (ko) 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
US11472863B2 (en) Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
JP6920230B2 (ja) アルファ−１アンチトリプシン融合ポリペプチド、それをコードする核酸構築体、及びそれらの組成物
KR101629702B1 (ko) 카잘-형 세린 프로테아제 억제제의 치료학적 적용
RU2722374C1 (ru) Высокогликозилированный слитый белок на основе фактора свертывания крови человека viii, способ его получения и его применение
KR20230064559A (ko) 인간 히알루로니다제 ph20과 약물을 포함하는 약학 조성물
JPH07503369A (ja) 血小板及び／又は内皮下層へのｖＷＦの結合の拮抗剤である抗血栓性ポリペプチド
JP2012522490A (ja) 第ｖｉｉｉ因子変異体および使用の方法
EP3164150B1 (en) Modified von willebrand factor
US12226451B2 (en) FGF-21 formulations
CN113105562B (zh) 突变型单链人凝血因子viii在制备融合蛋白中的应用
WO2018032639A1 (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
JP2025532618A (ja) 新規なヒアルロニダーゼｐｈ－２０変異体及びその使用
US20050037947A1 (en) Inhibition of drug binding to serum albumin
US7732167B2 (en) Interferon-α/β binding fusion proteins and therapeutic uses thereof
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用
TWI781415B (zh) 用於皮下注射之包含人類玻尿酸酶ph20變異體及藥物的醫藥組合物
JP2025526875A (ja) 改善された抗アルブミンナノボディおよびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250819

R150 Certificate of patent or registration of utility model

Ref document number: 7731288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150